Claims
- 1. A polypeptide comprising an amino acid sequence of the formula Y1-Y2-X3-Y4-X5-Y6-X7-Y8 whereY1 is a positively charged amino acid selected from the group consisting of Arg and Lys Y2 is Val, Leu, Ile or Met X3 is a natural alpha-amino acid Y4 is a negatively charged amino acid selected from the group consisting of Glu and Asp X5 is natural alpha-amino acid Y6 is a negatively charged amino acid selected from the group consisting of Glu and Asp X7 is natural alpha-amino acid Y8 is Thr or Ser wherein said polypeptide crosses the blood brain barrier or the gastrointestinal barrier.
- 2. The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ. ID. NO.:1.
- 3. The polypeptide according to claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ. ID. NO.:2.
- 4. The polypeptide according to claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ. ID. NO.:4.
- 5. A pharmaceutical composition comprising a polypeptide of claim 1, and a biological agent.
- 6. The pharmaceutical composition of claim 5 wherein said polypeptide comprises the amino acid sequence of SEQ. ID. NO.:4.
- 7. The composition of claim 5 further comprising a carrier.
- 8. The composition polypoptido of claim 5 further comprising a biological agent and a carrier.
- 9. A composition comprising the polypeptide of claim 1, with a therapeutic agent.
- 10. A polypeptide comprising a sequence selected from the group consisting of SEQ ID NO: 1, 2, 4, or 7.
- 11. The polypeptide according to claim 10, wherein said polypeptide comprises the amino acid sequence of SEQ. ID. NO.:7.
- 12. The polypeptide of claim 10 comprising the sequence of SEQ ID NO: 1.
- 13. The polypeptide of claim 10 comprising the sequence of SEQ ID NO.: 4.
- 14. The polypeptide of claim 10 comprising the sequence of SEQ ID NO: 2.
- 15. A pharmaceutical composition comprising a polypeptide containing the sequence of SEQ ID NO: 1, 2, 4 or 7 and a biological agent.
- 16. The pharmaceutical composition of claim 15 furthe comprising a carrier.
- 17. The pharmaceutical composition of claim 15 comprising said polypeptide and a therapeutic agent.
RELATED APPLICATIONS
The present application is based upon and claims the benefit of U.S. Provisional Application Serial No. 60/201,981 filed May 3, 2000.
Foreign Referenced Citations (3)
Number |
Date |
Country |
0599303 |
Jun 1994 |
EP |
WO 9856938 |
Dec 1998 |
WO |
WO 9922756 |
May 1999 |
WO |
Non-Patent Literature Citations (2)
Entry |
Pardridge et al., “Chimeric Peptides As A Vehicle For Peptide Pharmaceutical Delivery Through The Blood-Brain Barrier,” Biochemical and Biophysical Research Communications, 146(1):307-313 (Jul. 15, 1987). |
Taylor et al., “Designing Stable Blood-Brain Barrier-Permeable Prosaptide Peptides For Treatment of Central Nervous System Neurodegeneration,” The Journal of Pharmacology and Experimental Therapeutics, 293(2):403-409 (2000). |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/201981 |
May 2000 |
US |